PIK3CA and cancer: Previous studies have shown that concomitant inhibition of the PI3K and MAPK pathways by PI3K and MEK inhibition yields promising anti-cancer effects in vitro and in vivo [2, 18–26], and the combination of WX-554 and WX-037 demonstrated synergy in vitro and increased efficacy in vivo [5].